A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects

Protocol No
PULM-ANSUN-BIOPHARMA-FQ
Staff Member
Mark Barash
Phase
III
Summary

This project is being done to see if DAS181 can help doctors care for immunocompromised patients with lower respiratory tract infections caused by PIV.

Objective
Lower Respiratory Tract PIV Infection in Immunocompromised Subjects
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL